Multifunctional, Nanoparticle-Based, Therapies for the Treatment of Periodontal D

描述（由申请人提供）：本I期SBIR提案的目标是为牙周病的治疗提供改进的疗法。牙周病是一种口腔慢性感染性疾病，在美国大约有35%的成年人患有牙周病，也就是略多于4000万人。1-12在严重的情况下，牙周病会导致底层骨骼结构的破坏，需要手术拔牙和更换牙齿。仅在美国，治疗牙周病的费用估计在1984年每年为190亿美元。提出的创新是生产多功能，表面修饰的纳米颗粒载体，旨在与硬组织表面和细菌生物膜牢固结合，并可能提供多种治疗有效载荷。由于纳米颗粒可能与组织表面和细菌生物膜结合，因此载体可能在牙周袋内具有实质性（持久）的治疗效果，这是当前治疗方法的主要缺点。在牙周组织内定位和化学附着药物载体的能力是提出的创新的一个主要优点，因为传统的治疗方法都存在这样一个问题，即药物会被牙龈沟液（唾液）的周转迅速清除如果成功，这一创新将能够管理多种治疗化学物质，并在较长一段时间内以有效的水平将它们输送到牙周袋和牙龈组织，而无需临床医生的反复干预。

DESCRIPTION (provided by applicant): The objective of this Phase I SBIR proposal is to provide improved therapies for the treatment of periodontal disease. Periodontal Disease is a chronic infectious disease of the oral cavity that effects about 35 % of the adult population in the United States, or slightly more than 40 million people.1-12 In severe cases, periodontal disease can lead to a failure of the underlying bone structure and necessitate surgical extraction and replacement of the teeth. In the U.S alone, the cost of treating periodontal disease was estimated at $19 billion dollars annually in 19984. The innovation proposed is to produce multifunctional, surface-modified nanoparticle carriers that are designed to bind robustly to hard tissue surfaces and bacterial biofilms, and may deliver multiple therapeutic payloads. Because the nanoparticles may bind to tissue surfaces and to bacterial biofilms, the carriers may have substantive (long lasting) therapeutic effects within the periodontal pocket, a major shortcoming of current therapies. The ability to localize and chemically attach the drug-carrier within the periodontium is a major advantage of the proposed innovation, since conventional therapies all suffer from the fact that the drugs are rapidly cleared by the turnover of gingival crevicular fluid (saliva).7 The proposed innovation, if successful, will be capable of managing multiple therapeutic chemistries and deliver them to the periodontal pocket and gingival tissues at efficacious levels over an extended period of time, without repeated intervention from a clinician. PUBLIC HEALTH RELEVANCE: Periodontal Disease is a chronic infectious disease of the oral cavity that effects about 35 % of the adult population in the United States, or slightly more than 40 million people. This SBIR seeks to overcome the shortcomings of current therapies for periodontal disease, and to provide a therapy that is capable of managing multiple therapeutic chemistries, delivering them to disease sites over an extended period of time, without the repeated intervention from a clinician.